NASDAQ:NCEL NLS Pharmaceutics Q2 2026 Earnings Report $2.95 +0.06 (+2.08%) As of 09/25/2026 03:54 PM Eastern ProfileEarnings HistoryForecast NLS Pharmaceutics EPS ResultsActual EPS-$0.48Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANLS Pharmaceutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANLS Pharmaceutics Announcement DetailsQuarterQ2 2026Date9/18/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile NLS Pharmaceutics Earnings HeadlinesDer aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.August 27, 2026 | de.investing.comNewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium PricingJuly 31, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 27 at 1:00 AM | Banyan Hill Publishing (Ad)NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory BoardJuly 8, 2026 | globenewswire.comNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 DiabetesJuly 1, 2026 | globenewswire.comNewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformJune 15, 2026 | globenewswire.comSee More NLS Pharmaceutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NLS Pharmaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NLS Pharmaceutics and other key companies, straight to your email. Email Address About NLS PharmaceuticsNLS Pharmaceutics (NASDAQ:NCEL) AG is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly sleep-related conditions. The company’s research is based on the role of orexin, a neurotransmitter involved in regulating wakefulness, arousal and energy balance. NLS Pharmaceutics has developed a portfolio of small-molecule orexin receptor agonists, including AAZ-A-154 and AAZ-A-172. These investigational compounds are intended to address disorders associated with excessive daytime sleepiness and impaired wakefulness, including narcolepsy and other neurological conditions. The company’s programs remain subject to clinical development and regulatory review. The company was established in Switzerland and has operated as an international biotechnology business, with corporate activities centered in Europe and research and development directed toward potential global markets. NLS Pharmaceutics has been led by executives including Chief Executive Officer Alex Zwyer, who has been associated with the company since its early development.View NLS Pharmaceutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
